Results 61 to 70 of about 153,175,670 (281)

Inebilizumab in AQP4‐Seropositive NMOSD: One‐Year Follow‐Up From a Multicenter, Real‐World Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Real‐world evidence on inebilizumab among neuromyelitis optica spectrum disorder (NMOSD) patients is lacking. This study assessed inebilizumab among Chinese patients with aquaporin 4 autoantibody (AQP4‐IgG)‐seropositive NMOSD in a real‐world setting.
Mengcui Gui   +10 more
wiley   +1 more source

Hepatitis C : an emerging concern [PDF]

open access: yes, 1997
Hepatitis C has surfaced worldwide as a formidable concern to public health. Recent developments have sharpened methods of serological detectability, epidemiological study and patient treatment.
Gauci, Charmaine   +3 more
core  

Determinants of hepatitis C virus clinical outcomes [PDF]

open access: yes
Hepatitis C VIruS (HCY) infection is characterized by a broad spectrum of clinical outcomes. An estimated 14%-46% of individuals exposed to HCY are able to clear the virus, while the other portion develops chronic ...
Yee, Leland Jonathan
core   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source

Pesquisaje de AgsHB y de anti-HVC en pacientes con enfermedad inflamatoria intestinal crónica

open access: yesRevista Cubana de Higiene y Epidemiología, 1998
Se decide realizar un pesquisaje de AgsHB y anti-HVC en pacientes que padecen enfermedad inflamatoria intestinal crónica (EIIC) debido a que se ha producido un aumento en la frecuencia de presentación de esta afección.
Olga M. Hano García   +2 more
doaj  

Sustained virological response rates with direct-acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trials

open access: yesJournal of virus eradication, 2019
Objectives Under representation of black subjects in trials of hepatitis C virus (HCV) direct-acting antivirals (DAAs) complicates assessment of differential outcomes for black individuals vs non-black individuals.
K. Struble   +8 more
semanticscholar   +1 more source

Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors [PDF]

open access: yes, 2010
Hepatitis C virus (HCV) naturally infects only humans and chimpanzees. The determinants responsible for this narrow species tropism are not well defined.
Christiane Brohm   +25 more
core   +2 more sources

Anticuerpos del virus de la hepatitis C en pacientes con liquen plano bucal Hepatitis C virus antibodies in patients with oral lichen planus

open access: yesRevista Habanera de Ciencias Médicas, 2011
El liquen plano bucal es una enfermedad inflamatoria crónica cuya etiología permanece desconocida. Se acepta que representa una respuesta inmune mediada por células, en la que existe una interacción linfocito-epitelio, que culmina con la degeneración del
Mónica Elena Fernández Jiménez   +3 more
doaj  

Outcomes of Radiation Segmentectomy for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease versus Chronic Viral Hepatitis

open access: yesJournal of Hepatocellular Carcinoma, 2023
Cynthia De la Garza-Ramos,1 S Ali Montazeri,1 Kaitlyn R Musto,1 Melissa D Kapp,1 Andrew R Lewis,1 Gregory Frey,1 Ricardo Paz-Fumagalli,1 Sumera Ilyas,2 Denise M Harnois,3 Umair Majeed,4 Tushar Patel,3 Beau Toskich1 1Division of Interventional Radiology ...
De la Garza-Ramos C   +11 more
doaj  

Real‐World Safety of Concomitant Colchicine and Statin Therapy

open access: yesArthritis Care &Research, EarlyView.
Objective This study aimed to evaluate the risk of clinically meaningful muscle‐ and liver‐related outcomes associated with concomitant colchicine–statin therapy in a real‐world setting, and to determine whether concomitant therapy increases the incidence of toxicity compared with either agent alone.
Roni Meidan   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy